269 related articles for article (PubMed ID: 23678667)
21. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
22. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
23. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
24. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
26. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
27. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
29. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
30. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
Papadopoulos M; Patel D; Korologou-Linden R; Goto E; Soondrum K; Fell JME; Epstein J
Br J Clin Pharmacol; 2018 Apr; 84(4):694-699. PubMed ID: 29266387
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
33. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
34. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
[TBL] [Abstract][Full Text] [Related]
35. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
[No Abstract] [Full Text] [Related]
37. [Parenteral iron replacement].
Cynke E
Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
[No Abstract] [Full Text] [Related]
38. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
[TBL] [Abstract][Full Text] [Related]
39. When is high-dose intravenous iron repletion needed? Assessing new treatment options.
Gozzard D
Drug Des Devel Ther; 2011 Jan; 5():51-60. PubMed ID: 21340038
[TBL] [Abstract][Full Text] [Related]
40. Parenteral iron therapy: a single institution's experience over a 5-year period.
Laman CA; Silverstein SB; Rodgers GM
J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
